Back to Markets
NEMinerva Neurosciences Inc

Minerva Neurosciences Inc

NERVNASDAQ NMS - GLOBAL MARKET
Health CareBiotechnology

$4.91

-0.090000 (-1.80%)

As of 05/29/26 EDT · USD

Compare
Low: $1.55Current: $4.91High: $12.46

Key Statistics

Open

$4.98

Day High

$5.01

Day Low

$4.85

Prev. Close

$5.00

VolumeShares traded today.

56.84K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$228.75M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-0.17

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$12.46

52W LowLowest price over the past 52 weeks.

$1.55

50D MAAverage closing price over the last 50 trading days.

$5.95

200D MAAverage closing price over the last 200 trading days.

$4.51

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

-7.4%

1M

-23.2%

6M

+30.2%

YTD

+25.3%

1Y

+214.7%

About

MIN-117 is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD. In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.

www.minervaneurosciences.com/

Company Facts

SectorHealth Care
IndustryBiotechnology
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade NERV

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.